Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Abstract

Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.

Keywords

• COVID-19
• respiratory infections
• severe acute respiratory syndrome coronavirus 2
• SARS-CoV-2
• SARS
• coronavirus disease